- Conditions
- Metastatic Uveal Melanoma in the Liver
- Interventions
- SD-101, Nivolumab, Ipilimumab, Nivolumab and Relatlimab
- Drug · Biological
- Lead sponsor
- TriSalus Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,134
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Durvalumab, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
- Interventions
- nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Yana Najjar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Pittsburgh, Pennsylvania
- Conditions
- Malignant Neoplasm
- Interventions
- MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota
- Conditions
- Chronic Primary Immune Thrombocytopenia (ITP)
- Interventions
- Kedrion IVIG 10%
- Biological
- Lead sponsor
- Kedrion S.p.A.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Shirley, New York • Greenville, North Carolina
- Conditions
- Breast Cancer
- Interventions
- trastuzumab (Herceptin®), anastrazole (Arimidex®)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
- Conditions
- Breast Cancer
- Interventions
- Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Setrusumab
- Biological
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- TRK-950, Ramucirumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- Toray Industries, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Duarte, California • Irvine, California • Santa Monica, California + 6 more
- Conditions
- Lung Neoplasms, Carcinoma, Cancer of the Lung, Non-Small-Cell Lung Carcinoma
- Interventions
- Cetuximab, Cisplatin, Vinorelbine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 13
- States / cities
- Casa Grande, Arizona • Beverly Hills, California • Los Angeles, California + 10 more
- Conditions
- Melanoma
- Interventions
- BMS-982470 (recombinant interleukin-21), Ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 49
- States / cities
- Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more
- Conditions
- End Stage Renal Disease
- Interventions
- CMVIG
- Drug
- Lead sponsor
- Tampa General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Small Cell Lung Cancer
- Interventions
- BMS-986012 (anti-fucosyl-GM1), Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 3
- States / cities
- New York, New York • Durham, North Carolina • Winston-Salem, North Carolina
- Conditions
- Solid Tumor
- Interventions
- Tilsotolimod, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Newport Beach, California • Houston, Texas
- Conditions
- Kidney Transplant Rejection
- Interventions
- Imlifidase, Plasma Exchange
- Drug · Other
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more
- Conditions
- Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
- Interventions
- Intravenous immunoglobulin, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- Intravenous Immunoglobulin, Placebo
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Venetoclax, Bendamustine, Rituximab
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Urbana, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more
- Conditions
- Follicular Lymphoma
- Interventions
- Zevalin, Rituximab
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Sun City, Arizona • Athens, Georgia • Niles, Illinois + 2 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
- Interventions
- GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
- Conditions
- Obsessive-Compulsive Disorder, Children, Anxiety Disorder, Autoimmune Disease, PANDAS
- Interventions
- Gamunex Intravenous Immunoglobulin, Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 4 Years to 13 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Endometrial Cancer
- Interventions
- Cetuximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas